These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
342 related articles for article (PubMed ID: 24386667)
21. India's pharmaceutical industry: hype or high tech take-off? Malhotra P; Lofgren H Aust Health Rev; 2004 Nov; 28(2):182-93. PubMed ID: 15527398 [TBL] [Abstract][Full Text] [Related]
22. Drugmakers fight for good name. Stakes high, challenges many for providers who seek generic products. Becker C Mod Healthc; 2001 Aug; 31(35):28-33, 1. PubMed ID: 11550428 [TBL] [Abstract][Full Text] [Related]
24. [Free trade agreements make the drugs more expensive]. Jeppsson A Lakartidningen; 2009 Nov 18-24; 106(47):3181. PubMed ID: 20082499 [No Abstract] [Full Text] [Related]
25. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments. Yvon AM Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596 [No Abstract] [Full Text] [Related]
26. Strategic options for brand-name prescription drugs when patents expire. Mehta SC; Mehta SS Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309 [TBL] [Abstract][Full Text] [Related]
27. Generics battle brand names over mortality of drug patents. Betz R J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008 [No Abstract] [Full Text] [Related]
28. The new patent regime and disease priorities in India. Gupta I; Guin P; Trivedi M Glob Public Health; 2013; 8(1):37-54. PubMed ID: 22845021 [TBL] [Abstract][Full Text] [Related]
29. Branded drug reformulation: the next brand vs. generic antitrust battleground. Amoresano GV Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032 [No Abstract] [Full Text] [Related]
30. The wake of FTC v. Actavis: practical implications on the pharmaceutical industry. Ritter M; Tempesta J; Ragusa P Pharm Pat Anal; 2014 Jul; 3(4):345-7. PubMed ID: 25291307 [No Abstract] [Full Text] [Related]
31. Pharmaceutical patent settlements: the antitrust risks. Balto DA Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464 [No Abstract] [Full Text] [Related]
33. Pharmaceuticals and Medical Devices: Business Practices. Steiner DJ; Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-38. PubMed ID: 28252886 [No Abstract] [Full Text] [Related]
34. Brazil and USA at loggerheads over production of generic antiretrovirals. Ahmad K Lancet; 2001 Feb; 357(9254):453. PubMed ID: 11273079 [No Abstract] [Full Text] [Related]
35. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms. Panattoni LE J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873 [TBL] [Abstract][Full Text] [Related]
36. An ethical dilemma. Patents & profits v. access & affordability. Blasi AE J Leg Med; 2012 Jan; 33(1):115-28. PubMed ID: 22439710 [No Abstract] [Full Text] [Related]
37. Lowering the cost of prescription drugs. Jindal B J La State Med Soc; 2003; 155(1):51. PubMed ID: 12656276 [No Abstract] [Full Text] [Related]
38. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act. Apel BT Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458 [TBL] [Abstract][Full Text] [Related]
39. Patent indicators: a window to pharmaceutical market success. Guo Y; Hu Y; Zheng M; Wang Y Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022 [TBL] [Abstract][Full Text] [Related]
40. A shift on "pay for delay"--reopening doors for pharmaceutical competition? Hemphill Kraus EJ N Engl J Med; 2012 Nov; 367(18):1681-3. PubMed ID: 23113478 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]